Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan + Prednisone + Revlimid as induction therapy in elderly newly diagnosed multiple myeloma patients
2004-000669-36Phase 2Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoints: Dose-limiting toxicity of Revlimid in combination with melphalan + prednisone and Maximum tolerated dose of Revlimid in combination with melphalan + prednisone. Started Nov 2009; status: active.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2004-000669-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000669-36.